Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2006-01-18

Last Posted Date: 2021-03-10

Lead Sponsor: German High-Grade Non-Hodgkin's Lymphoma Study Group

Target Recruit Count: 700

Registration Number: NCT00278408

Locations: 🇩🇪
Virngrund-Klinik Ellwangen, Ellwangen, Germany
🇩🇪
Klinikum Bayreuth, Bayreuth, Germany
🇩🇪
University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany

and more 76 locations

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Phase 2

Completed

Conditions: Prolymphocytic Leukemia

First Posted Date: 2006-01-18

Last Posted Date: 2018-05-11

Lead Sponsor: German CLL Study Group

Target Recruit Count: 17

Registration Number: NCT00278213

Locations: 🇦🇹
Allgemeines Krankenhaus - Universitatskliniken, Vienna, Austria
🇦🇹
Hanuschkrankenhaus, Vienna, Austria
🇩🇪
Allgemeinen Krankenhaus Celle Kinderklinik, Celle, Germany

and more 16 locations

Partial Breast Irradiation With Chemotherapy

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: Doxorubicin
Radiation: radiation

First Posted Date: 2006-01-18

Last Posted Date: 2020-02-19

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 27

Registration Number: NCT00278109

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2006-01-18

Last Posted Date: 2021-03-11

Lead Sponsor: German High-Grade Non-Hodgkin's Lymphoma Study Group

Target Recruit Count: 592

Registration Number: NCT00278421

Locations: 🇩🇪
Klinikum Lippe - Lemgo, Lemgo, Germany
🇩🇪
Onkologische Schwerpunktpraxis, Wendlingen, Germany
🇩🇪
Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany

and more 73 locations

Hematopoietic Stem Cell Support in Vasculitis

Phase 1

Terminated

Conditions: Vasculitis

Interventions: Biological: Autologous Stem Cell Transplant
Biological: Allogeneic Stem Cell Transplant
Drug: Cyclophosphamide
Drug: ATG (rabbit)
Drug: Campath-1h
Drug: G-CSF
Drug: Fludarabine
Drug: Mesna
Drug: Tacrolimus

First Posted Date: 2006-01-18

Last Posted Date: 2018-08-02

Lead Sponsor: Northwestern University

Target Recruit Count: 7

Registration Number: NCT00278512

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2006-01-13

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00276731

Locations: 🇬🇧
Institute of Child Health at University of Bristol, Bristol, England, United Kingdom
🇬🇧
Royal London Hospital, London, England, United Kingdom
🇬🇧
Sir James Spence Institute of Child Health, Newcastle-Upon-Tyne, England, United Kingdom

and more 18 locations

Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer

Phase 2

Conditions: Liver Cancer

First Posted Date: 2006-01-13

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 47

Registration Number: NCT00276705

Locations: 🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧
Royal London Hospital, London, England, United Kingdom
🇬🇧
Institute of Child Health at University of Bristol, Bristol, England, United Kingdom

and more 17 locations

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2006-01-13

Last Posted Date: 2016-09-26

Lead Sponsor: German CLL Study Group

Target Recruit Count: 30

Registration Number: NCT00276809

Locations: 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪
Universitatsklinikum Heidelberg, Heidelberg, Germany
🇩🇪
University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany

and more 9 locations

Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma

Phase 3

Terminated

Conditions: Lymphoma

First Posted Date: 2006-01-11

Last Posted Date: 2013-07-10

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 600

Registration Number: NCT00275106

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧
Royal Manchester Children's Hospital, Manchester, England, United Kingdom
🇩🇪
Kinderklinik, Giessen, Germany

and more 18 locations

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: filgrastim
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2006-01-11

Last Posted Date: 2018-05-11

Lead Sponsor: German CLL Study Group

Target Recruit Count: 169

Registration Number: NCT00275015

Locations: 🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch, Berlin, Germany
🇩🇪
Internistische Praxis - Trier, Trier, Germany

and more 50 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy